HPTN Publications

Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, Rose SM, Latkin CA, Metzger DS, Lancaster KE, Go VF, Dvoriak S, Mollan KR, Reifeis SA, Piwowar-Manning E, Richardson P, Hudgens MG, Hamilton EL, Sugarman J, Eshleman SH, Susami H, Chu VA, Djauzi S, Kiriazova T, Bui DD, Strathdee SA, Burns DN . A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018, 392: 747-759

Mills L, Ndimande-Khoza MN, Velloza J, Atujuna M, Chitukuta M, Hosek S, Chauke H, Musara P, Mangxilana N, Mutero P, Makhale LM, Tauya T, Celum C, Delany-Moretlwe S; HPTN 082 study team. . Motivations for Starting and Stopping PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial. AIDS Behav. 2025, 29: 2408-2419

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team . Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014, 65: 33-41

Mitchell K, Dimitrov D, Hughes J, Moore M, Vittinghoff E, Liu A, Cohen M, Beyrer C, Donnell D, Boily MC . Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. Epidemics. 2020, 33

Mitchell KM, Dimitrov D, Hughes JP, Xia F, Donnell D, Amico KR, Bokoch K, Chitwarakorn A, Bekker LG, Holtz TH, Mannheimer S, Grant RM, Boily MC . In what circumstances could non-daily pre-exposure prophylaxis for HIV substantially reduce program costs?. AIDS. 2018, 32: 809-818

Mitchell KM, Hoots B, Dimitrov D, German D, Flynn C, Farley JE, Gelman M, Hughes JP, Donnell D, Adeyeye A, Remien RH, Beyrer C, Paz-Bailey G, Boily MC . Improvements in the HIV Care Continuum Needed to Meaningfully Reduce HIV Incidence Among Men Who Have Sex with Men in Baltimore, US: A Modelling Study for HPTN 078. J Int AIDS Soc. 2019, 22: e25246

Mkhize NN, Yssel AEJ, Kaldine H, van Dorsten RT, Woodward Davis AS, Beaume N, Matten D, Lambson B, Modise T, Kgagudi P, York T, Westfall DH, Giorgi EE, Korber B, Anthony C, Mapengo RE, Bekker V, Domin E, Eaton A, Deng W, DeCamp A, Huang Y, Gilbert PB, Gwa . Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog. 2023, 19: e1011469

Mohammed Limbada, David Macleod, Vasty Situmbeko, Ellen Muhau, Osborn Shibwela, Bwalya Chiti, Sian Floyd, Albertus J Schaap, Richard Hayes, Sarah Fidler, Helen Ayles . Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial. Lancet HIV. 2021, 9: E13-E23